Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i>-Mutant Melanoma.-论文-万方医学网

第一作者： Antoni,Ribas

第一单位： Jonsson Comprehensive Cancer Center at University of California, Los Angeles, Los Angeles, California. aribas@mednet.ucla.edu.

作者： Antoni,Ribas ^[1] ; Adil,Daud ^[2] ; Anna C,Pavlick ^[3] ; Rene,Gonzalez ^[4] ; Karl D,Lewis ^[5] ; Omid,Hamid ^[6] ; Thomas F,Gajewski ^[7] ; Igor,Puzanov ^[8] ; Matthew,Wongchenko ^[9] ; Isabelle,Rooney ^[9] ; Jessie J,Hsu ^[9] ; Yibing,Yan ^[9] ; Erica,Park ^[9] ; Grant A,McArthur ^[10]

作者单位： Jonsson Comprehensive Cancer Center at University of California, Los Angeles, Los Angeles, California. aribas@mednet.ucla.edu. ^[1] Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California. ^[2] NYU Langone Medical Center, New York, New York. ^[3] University of Colorado Comprehensive Cancer Center, Aurora, Colorado. ^[4] Anschutz Cancer Pavilion, University of Colorado Comprehensive Cancer Center, Aurora, Colorado. ^[5] The Angeles Clinic and Research Institute, Los Angeles, California. ^[6] The University of Chicago, Chicago, Illinois. ^[7] Roswell Park Comprehensive Cancer Center, Buffalo, New York. ^[8] Genentech, Inc., South San Francisco, California. ^[9] Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia, and University of Melbourne, Parkville, Victoria, Australia. ^[10]

主题词成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);吖丁啶类(Azetidines);队列研究(Cohort Studies);无病生存(Disease-Free Survival);女(雌)性(Female);随访研究(Follow-Up Studies);人类(Humans);男(雄)性(Male);最大耐受剂量(Maximum Tolerated Dose);黑色素瘤(Melanoma);中年人(Middle Aged);突变(Mutation);哌啶类(Piperidines);原癌基因蛋白质B-raf(Proto-Oncogene Proteins B-raf);皮肤肿瘤(Skin Neoplasms);治疗结果(Treatment Outcome);青年人(Young Adult)

DOI 10.1158/1078-0432.CCR-18-4180

PMID 31732523

发布时间 2020-10-01

检索历史清除

Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i>-Mutant Melanoma.

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i>-Mutant Melanoma.

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

检索历史清除